32

BrainStorm

January 17, 2023

George Vradenburg and the Future of Alzheimer's Advocacy - Part 1

George Vradenburg and the Future of Alzheimer's Advocacy - Part 1

About This Episode

The Food and Drug Administration expedited approval of Lecanemab, a drug developed by Eisai and Biogen, that demonstrated positive results in slowing Alzheimer's disease. What does this mean for the future of Alzheimer’s advocacy?

In this episode of BrainStorm, host Meryl Comer talks with George Vradenburg, Chairman and Co-Founder of UsAgainstAlzheimer’s, Convener of Global CEOi and Co-Convener with the World Economic Forum of the Davos Alzheimer’s Collaborative.  They discuss the immediate implications of the drug approval, how it will impact the Alzheimer’s movement, and what it means for the future of Alzheimer’s disease. 

Do you have feedback or an idea for the podcast? Send us a note at [email protected].
 

Support the show

BrainStorm Feed

90
July 15, 2025 | 21:48

The Longevity Paradox: Health Span vs. Life Span with Paul Irving

What's the purpose of a long life if our brains can't enjoy it? Paul Irving, Senior Advisor at the Milken Institute on the Future of Longevity and Dean of Faculty at USC's Leonard Davis School of Gerontology, challenges conventional thinking about aging and longevity in a conversation with host, Meryl Comer.
LISTEN NOW
89
July 1, 2025 | 16:18

Paul Irving and The Invisible Workforce: Why Caregiving is a Personal and an Economic Crisis

In this episode of BrainStorm, Paul Irving discusses the PBS documentary produced by Bradley Cooper called Caregiving with host Meryl Comer.
LISTEN NOW
88
June 17, 2025 | 23:39

Breaking the Silence: Jay Reinstein’s Mission to End Alzheimer's Stigma

In this episode of BrainStorm, host Meryl Comer talks with Jay Reinstein, a former assistant city manager in North Carolina, about his 12 to15-month journey involving neuropsychological testing and brain scans before being diagnosed with early-onset Alzheimer's at age 57.
LISTEN NOW